| Literature DB >> 31861148 |
Iria Bravo1,2, Cristina Gutiérrez-Sánchez1,2, Tania García-Mendiola1,2,3, Mónica Revenga-Parra1,2,3, Félix Pariente1,3, Encarnación Lorenzo1,2,3.
Abstract
This work reports on the advantages of using carbon nanodots (CNDs) in the development of reagent-less oxidoreductase-based biosensors. Biosensor responses are based on the detection of H2O2, generated in the enzymatic reaction, at 0.4 V. A simple and fast method, consisting of direct adsorption of the bioconjugate, formed by mixing lactate oxidase, glucose oxidase, or uricase with CNDs, is employed to develop the nanostructured biosensors. Peripherical amide groups enriched CNDs are prepared from ethyleneglycol bis-(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid and tris(hydroxymethyl)aminomethane, and used as precursors. The bioconjugate formed between lactate oxidase and CNDs was chosen as a case study to determine the analytical parameters of the resulting L-lactate biosensor. A linear concentration range of 3.0 to 500 µM, a sensitivity of 4.98 × 10-3 µA·µM-1, and a detection limit of 0.9 µM were obtained for the L-lactate biosensing platform. The reproducibility of the biosensor was found to be 8.6%. The biosensor was applied to the L-lactate quantification in a commercial human serum sample. The standard addition method was employed. L-lactate concentration in the serum extract of 0.9 ± 0.3 mM (n = 3) was calculated. The result agrees well with the one obtained in 0.9 ± 0.2 mM, using a commercial spectrophotometric enzymatic kit.Entities:
Keywords: L-lactate biosensor; carbon nanodots; electrochemical techniques; glucose oxidase; lactate oxidase; nanomaterials; oxidoreductase-based biosensors; uricase
Mesh:
Substances:
Year: 2019 PMID: 31861148 PMCID: PMC6960740 DOI: 10.3390/s19245576
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.576
Figure 1Cyclic voltammograms of SPAuE (black), Enz/SPAuE (red), Enz–CNDs/SPAuE (blue) when (A) LOx, (B) GOx, and (C) UOx were used, in the presence of 0.5 mM L-lactate, 1.0 mM glucose, and 1.0 mM uric acid (A, B, and C, respectively) and Enz–CNDs/SPAuE in the absence of substrate (grey). (D) Cyclic voltammograms of CNDs/SPAuE in 0.1 M phosphate buffer (pH 7.0) in the absence (black) and presence (red) of 0.5 mM H2O2. Scan rate: 0.01 V/s.
Scheme 1Enzymatic process for the bioconjugate LOx–CNDs.
Figure 2UV-Visible absorption spectra of (A) LOx and (C) the bioconjugate LOx–CNDs, and fluorescence emission spectra (λex= 350 nm) of (B) LOx and (D) the bioconjugate LOx–CNDs (solid) and CNDs (dotted), in the absence (black) and in the presence (red) of 0.5 mM L-lactate in 0.1 M phosphate buffer (pH 7.0). Taken after 30 minutes L-lactate addition.
Figure 3Fluorescence micrographs of (A) CNDs, (B) LOx–CNDs bioconjugate, and (C) LOx, at 20× magnification.
Figure 4Tapping-mode AFM topographic images of a (A) LOx–CNDs bioconjugate, and (B) LOx. Inset in B shows a photograph of a dimer formed by the LOX. All the experiments were carried out on a gold plate.
Figure 5Nyquist diagrams in 0.1 M phosphate buffer (pH 7.0) containing 10 mM K3Fe(CN)6/10 mM K4Fe(CN)6 for SPAuE (□), LOx/SPAuE (∆) and LOx–CNDs/SPAuE (○). Blue lines correspond to the fitting of the experimental data, to the shown equivalent circuit.
Figure 6Chronoamperometric biosensor response constructed from the bioconjugate LOx–CNDs in the presence of increasing L-lactate concentrations in 0.1 M phosphate buffer (pH 7.0). Inset: calibration curve.
Analytical parameters of some L-lactate biosensors based on LOx.
| Electrode | Modification | LOD (μM) | Linear Range (μM) | Matrix | Reference |
|---|---|---|---|---|---|
| SPCE | LOx/PtNp–CNF–PDDA | 11.1 | 25–1500 | sweat | [ |
| GCE | LOx/FcMe2–LPEI | 3 | up to 5000 | - | [ |
| Au | LOx–BSA–GA | 5 | 5–1000 | wine | [ |
| SPCE | LOx/rGO–DHS | 2.9 | up to 800 | white wine | [ |
| SPCE | LOx–Cu–MOF/CS/Pt | 0.75 | 0.75–1000 | wine, saliva, sweat | [ |
| SPCE | LOx–[Fe(CN)6]3+ | - | 390–16600 | tears | [ |
| Au | LOx/pMB/Au–MWCNTs | 2.4 | 10–200 | interstitial fluid | [ |
| SPAuE | LOx–CNDs | 0.9 | up to 500 | human serum | this work |
SPCE: screen printed carbon electrode; PtNp–CNF: platinum nanoparticle decorated carbon nanofibers; PDDA: poly(diallyldimethylammonium) chloride; GCE: glassy carbon electrode; FcMe2: dimethylferrocene; LPEI: linear polyethyleneimine; BSA: bovine serum albumin; GA: glutaraldehyde; rGO-DHS: 3,4-dihydroxysalophen modified reduced graphene oxide; Cu-MOF: copper metallic framework; CS: chitosan; pMB: poly-methylene blue; MWCNTs: multiwalled carbon nanotubes.
Effect of the potentially interfering compounds on the biosensor response.
| Substance | Relative intensity | |
| 1:0.1 | 1:1 | |
| Glucose | 1.1 | 1.1 |
| Uric acid | 1.0 | 1.1 |
| Acetaminophen | 1.3 | 2.3 |
| Ascorbic acid | 0.5 | 0.4 |
| Strategies to eliminate the ascorbic acid interference | ||
| Ascorbic acid | ||
| Nafion® | 0.7 | 0.6 |
| AOx | 0.9 | 1.1 |
Relative intensity = IL + I/IL. IL: biosensor response to 0.50 mM·L-lactate; IL + I: biosensor response to 0.50 mM·L-lactate in the presence of interfering substance at a final concentration of 0.05 mM (1:0.1) or 0.5 mM (1:1).